This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock ELTX vs. OCS, DAWN, VIR, MNMD, KURA, BGM, TNGX, GOSS, IMTX, and RZLTShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Oculis (OCS), Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Mind Medicine (MindMed) (MNMD), Kura Oncology (KURA), BGM Group (BGM), Tango Therapeutics (TNGX), Gossamer Bio (GOSS), Immatics (IMTX), and Rezolute (RZLT). These companies are all part of the "med - biomed/gene" industry. Elicio Therapeutics vs. Its Competitors Oculis Day One Biopharmaceuticals Vir Biotechnology Mind Medicine (MindMed) Kura Oncology BGM Group Tango Therapeutics Gossamer Bio Immatics Rezolute Oculis (NASDAQ:OCS) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership. Which has more volatility & risk, OCS or ELTX? Oculis has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Elicio Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Do analysts prefer OCS or ELTX? Oculis presently has a consensus target price of $35.75, indicating a potential upside of 115.10%. Elicio Therapeutics has a consensus target price of $13.00, indicating a potential upside of 14.84%. Given Oculis' higher possible upside, equities analysts clearly believe Oculis is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Elicio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in OCS or ELTX? 22.3% of Oculis shares are held by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are held by institutional investors. 28.7% of Elicio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to OCS or ELTX? In the previous week, Oculis had 1 more articles in the media than Elicio Therapeutics. MarketBeat recorded 4 mentions for Oculis and 3 mentions for Elicio Therapeutics. Oculis' average media sentiment score of 0.58 beat Elicio Therapeutics' score of 0.00 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OCS or ELTX more profitable? Elicio Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,958.12%. Elicio Therapeutics' return on equity of 0.00% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,958.12% -90.31% -67.85% Elicio Therapeutics N/A N/A -175.83% Which has higher earnings & valuation, OCS or ELTX? Elicio Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$780K930.29-$97.43M-$2.67-6.22Elicio Therapeutics$2.30M80.42-$51.90M-$6.95-1.63 SummaryOculis and Elicio Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.95M$3.15B$5.80B$10.46BDividend YieldN/A2.36%5.61%4.57%P/E RatioN/A21.0580.3026.85Price / Sales80.42450.86558.45179.64Price / CashN/A44.8326.0131.15Price / Book-10.999.6215.686.42Net Income-$51.90M-$53.02M$3.30B$271.73M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics1.0534 of 5 stars$11.32-1.3%$13.00+14.8%+123.3%$184.95M$2.30M0.00N/AOCSOculis2.7814 of 5 stars$17.23+0.2%$35.75+107.5%+38.5%$752.26M$780K-6.452Analyst DowngradeDAWNDay One Biopharmaceuticals2.98 of 5 stars$7.26-2.0%$25.29+248.3%-53.9%$743.64M$131.16M-7.6460Positive NewsVIRVir Biotechnology3.6243 of 5 stars$5.13-2.1%$26.80+422.4%-33.2%$712.64M$14.39M-1.28580MNMDMind Medicine (MindMed)2.3186 of 5 stars$9.33-4.5%$24.71+164.9%+51.4%$709.92MN/A-6.1040KURAKura Oncology4.0092 of 5 stars$8.17+2.0%$24.10+195.0%-60.6%$709.16M$53.88M-3.62130Gap UpHigh Trading VolumeBGMBGM Group0.225 of 5 stars$7.28-2.5%N/A+25.7%$707.78M$26.85M0.00298Gap DownTNGXTango Therapeutics2.0485 of 5 stars$6.36-6.7%$10.50+65.1%-8.4%$707.61M$42.07M-4.7890GOSSGossamer Bio3.9655 of 5 stars$3.11+12.3%$8.50+173.3%+190.5%$707.16M$40.24M-5.02180Analyst DowngradeGap UpHigh Trading VolumeIMTXImmatics2.8424 of 5 stars$5.81+0.3%$14.67+152.4%-44.5%$706.21M$130.13M-8.94260RZLTRezolute3.1914 of 5 stars$8.10+0.2%$11.67+44.0%+51.6%$704.67MN/A-7.0440Trending NewsEarnings ReportAnalyst RevisionGap Up Related Companies and Tools Related Companies OCS Competitors DAWN Competitors VIR Competitors MNMD Competitors KURA Competitors BGM Competitors TNGX Competitors GOSS Competitors IMTX Competitors RZLT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELTX) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThis Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top...Crypto 101 Media | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
